CN108367006B - 用于治疗血液癌症的赛度替尼 - Google Patents

用于治疗血液癌症的赛度替尼 Download PDF

Info

Publication number
CN108367006B
CN108367006B CN201680073276.XA CN201680073276A CN108367006B CN 108367006 B CN108367006 B CN 108367006B CN 201680073276 A CN201680073276 A CN 201680073276A CN 108367006 B CN108367006 B CN 108367006B
Authority
CN
China
Prior art keywords
cerdulatinib
patient
pharmaceutically acceptable
lymphoma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680073276.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108367006A (zh
Inventor
格雷戈里·科菲
冯佳佳
安德鲁·斯蒂尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN108367006A publication Critical patent/CN108367006A/zh
Application granted granted Critical
Publication of CN108367006B publication Critical patent/CN108367006B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680073276.XA 2015-12-04 2016-12-02 用于治疗血液癌症的赛度替尼 Active CN108367006B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
US201662342755P 2016-05-27 2016-05-27
US201662342727P 2016-05-27 2016-05-27
US62/342,727 2016-05-27
US62/342,755 2016-05-27
US201662371145P 2016-08-04 2016-08-04
US62/371,145 2016-08-04
PCT/US2016/064824 WO2017096303A2 (en) 2015-12-04 2016-12-02 Cerdulatinib for treating hematological cancers

Publications (2)

Publication Number Publication Date
CN108367006A CN108367006A (zh) 2018-08-03
CN108367006B true CN108367006B (zh) 2021-12-31

Family

ID=57614468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073276.XA Active CN108367006B (zh) 2015-12-04 2016-12-02 用于治疗血液癌症的赛度替尼

Country Status (8)

Country Link
US (2) US10736895B2 (https=)
EP (1) EP3383396B1 (https=)
JP (1) JP6944936B2 (https=)
CN (1) CN108367006B (https=)
AU (1) AU2016363005A1 (https=)
CA (1) CA2950640A1 (https=)
ES (1) ES2959692T3 (https=)
WO (1) WO2017096303A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196385A1 (en) 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
SG11202005781WA (en) * 2018-01-09 2020-07-29 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
EP3788035B1 (en) 2018-05-04 2024-08-07 Alexion Pharmaceuticals, Inc. Solid forms of cerdulatinib
EP3787628A1 (en) * 2018-05-04 2021-03-10 Portola Pharmaceuticals, Inc. Methods for treating lymphoma
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
SG11202108770TA (en) * 2019-02-15 2021-09-29 Janssen Biotech Inc Combination therapy for treatment of b-cell malignancies
US20230181581A1 (en) * 2020-05-26 2023-06-15 Alexion Pharmaceuticals, Inc. Circulating b cell subpopulations in indolent b cell lymphoma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
MX2009000769A (es) 2006-07-21 2009-01-28 Novartis Ag Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak.
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA024109B1 (ru) 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
AR076550A1 (es) 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
NZ595708A (en) 2009-05-26 2014-03-28 Abbvie Bahamas Ltd Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20110130415A1 (en) 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof
US9357229B2 (en) 2010-07-28 2016-05-31 Qualcomm Incorporated Coding motion vectors in video coding
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016196385A1 (en) 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
EP3788035B1 (en) 2018-05-04 2024-08-07 Alexion Pharmaceuticals, Inc. Solid forms of cerdulatinib

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Phase I Open-Label，Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies;PATEL MANISH ET AL;《BLOOD》;20141231;摘要 *
BLUNT MATTHEW D ET AL.The Syk\Jak Inhibitor Cerdulatinib(PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling.《BLOOD》.2015,摘要. *
Cerdulatinib，a novel dual SYK/JAK kinase inhibitor，has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma;MA JIAO ET AL:;《ONCOTARGET》;20140609;摘要，讨论 *
The Syk\Jak Inhibitor Cerdulatinib(PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling;BLUNT MATTHEW D ET AL;《BLOOD》;20151203;摘要 *

Also Published As

Publication number Publication date
US20180353506A1 (en) 2018-12-13
ES2959692T3 (es) 2024-02-27
US20210000827A1 (en) 2021-01-07
JP2018535996A (ja) 2018-12-06
EP3383396A2 (en) 2018-10-10
US10736895B2 (en) 2020-08-11
EP3383396B1 (en) 2023-07-12
WO2017096303A2 (en) 2017-06-08
CN108367006A (zh) 2018-08-03
JP6944936B2 (ja) 2021-10-06
AU2016363005A1 (en) 2018-07-05
CA2950640A1 (en) 2017-06-04
US11446300B2 (en) 2022-09-20
WO2017096303A3 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
CN108367006B (zh) 用于治疗血液癌症的赛度替尼
JP7323592B2 (ja) 癌を治療するための併用療法
US12350269B2 (en) Cerdulatinib for the treatment of b-cell malignancies
CN106659716A (zh) 阿吡莫德组合物及其使用方法
KR102849513B1 (ko) 암 치료 방법
CN114828842A (zh) 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
Pilehvari et al. The role of genetics and synergistic effect of targeting common genetic mutations in Acute Lymphoblastic Leukemia (ALL)
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK40061501A (en) Combination therapy for treating cancer
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies
Puvvada et al. Emerging Frontiers in Therapeutics of Diffuse Large B Cell Lymphoma: Epigenetics and B Cell Receptor Signaling

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant